Utility of novel 2-furanones in synthesis of other heterocyclic compounds having anti-inflammatory activity with dual COX2/LOX inhibition.

Inflammation is associated with the development of several diseases comprising cancer and cardiovascular disease. Agents that suppress cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, besides chemokines have been suggested to minimise inflammation. Here, a variety of novel heterocyclic and non-heterocyclic compounds were prepared from novel three furanone derivatives. The structures of all synthesised compounds were confirmed by elemental and spectral analysis including mass, IR, and 1H-NMR spectroscopy. Anti-inflammatory activities of these synthesised compounds were examined in vitro against COX enzymes, 15-LOX, and tumour necrosis factor-α (TNF-α), using inhibition screening assays. The majority of these derivatives showed significant to high activities, with three pyridazinone derivatives (5b, 8b, and 8c) being the most promising anti-inflammatory agents with dual COX-2/15-LOX inhibition activities along with high TNF-α inhibition activity.

Introduction

Inflammation is a protective physiological defence mechanism provided by the body immune system in response to toxins, infectious pathogens, an class="Disease">nd local injury. It occurs as a result of biosynthesis of pro-inflammatory mediators (leukotrienes [LTs] and prostaglandins [PGs]) from arachidonic acid (AA) by the action of the enzymes lipoxygenase (LOX) and cyclooxygenase (COX), respectively. Although inflammation is a normal defence mechanism, persistent/untreated inflammation leads to complicated events with release of many mediators that can turn the condition to be harmful and may lead to the development of certain diseases, as asthma, rheumatoid arthritis, atherosclerosis, diabetes, and cancer. Therefore, anti-inflammatory agents may be helpful in the management of inflammatory disorders. Anti-inflammatory effects of various compounds may result mainly from their ability to inhibit some of the key enzymes involved in inflammation and/or cell signalling pathways such as COX and LOX.

Thus, inhibition of these enzymes may be valuable treatment for inflammatory con class="Disease">nditions. In the human system, COX occurs in two isoforms: COX-1 and COX-2. Both isoforms catalyse a COX reaction in which they act on AA as substrate. COX isoforms are haem containing enzymes that demonstrate distinctive expression profiles and roles in numerous physiological processes. COX-1 is constitutive isoform and is found in the gastrointestinal (GI)-tract, renal collecting tubules, and platelets and is believed to be responsible for the maintenance of physiological homeostasis such as renal function and GI integrity through production of gastroprotective PGs. On the other hand, the inducible isoform; COX-2 is released during tissue injury and induced by many kinds of inflammatory mediators; playing an important role in the proinflammatory PGs biosynthesis.

Inhibition of both isoforms of COX by classical nonsteroidal anti-inflammatory drugs (NSAIDs) leads to inhibition of gastroprotective n class="Chemical">PGs produced via the COX-1 pathway; which occurs along with suppression of the pathological COX effects; resulting in the GI toxicities accompanying the use of numerous NSAIDs as GI irritation, bleeding, and ulceration. Several studies revealed that COX-2 is highly expressed in a wide range of cancer tissues, such as colon, breast, and prostate, suggesting that it may control several cellular processes. Thus, selective COX-2 inhibitors have been extensively investigated for the treatment and prevention of a variety of cancers.

Also, COX-2 is foun class="Disease">nd in wide range of tissues e.g. brain, spinal cord, and kidneys, as well as many cells like vascular endothelium, suggesting that this isoenzyme may play a more complex physiological role than was expected,.

However, potent selective COX-2 inhibitors, which were used instead of n class="Chemical">NSAIDs; also showed disadvantages as incidence of vascular-diseases. AA; which is the substrate of COX enzymes, is also converted by LOX enzyme to several lipid mediators recognised as eicosanoids. LOXs are an exceptional group of non-haem iron-containing enzymes that catalyse the peroxidation of polyunsaturated fatty acids viz. AA and linoleic acid to their hydroperoxides. 15-LOXs are implicated in a variety of human diseases, like the oxidative alteration of low-density lipoproteins and thus, the progression of atherosclerosis. In addition to many neurodegenerative diseases as Alzheimer’s disease, 15-LOX-1 inhibition has been reported to be a focal point to decrease the biosynthesis of eoxines, which are known to be pro-inflammatory mediators and promotors for cancer disease. Thus, some literature work has been targeting 15-LOX-1.

Yet, the use of LOX-inhibitors might represent an insufficient single therapeutic model in inflammatory diseases other than n class="Disease">asthma,. It was discovered that dual inhibition of the COX and LOX pathways could produce a wider spectrum of anti-inflammatory effects and can limit the vascular-changes seen during inflammation and leukocyte-induced GI damage.

2-Furanones; well-known heterocyclic derin class="Chemical">vatives; had attracted a great attention during the last decade due to facile ring opening and conversion to other heterocycles; pyrrolones, pyridazinones, pyrazoles, and oxadizoles. These heterocycles acquired an obvious medicinal interest as antimicrobial, antiviral, antimycobacterial,, and anti-cancer agents. Literature is enriched with different 2-furanones subjected to ring opening to form 2-pyrrolone, pyridazinone, and oxadiazole derivatives, all have high activity as anti-inflammatory,. As shown in Figure 1, 2-furanone derivatives Ia–c were reported to exhibit comparable anti-inflammatory activity to that of diclofenac,,, while 2-pyrrolone derivatives II, IIIa–b, and IV were reported to have comparable anti-inflammatory activity to that of indomethacin, ibuprofen, and diclofenac, respectively, .

Figure 1.

2-furanones, 2-pyrrolones, pyridazinones, and oxadiazoles as potent anti-inflammatory agents.

2-furanones, n class="Chemical">2-pyrrolones, pyridazinones, and oxadiazoles as potent anti-inflammatory agents.

Many pyridazinone derin class="Chemical">vatives were also reported as Va,b; which have superior anti-inflammatory activities over celecoxib and indomethacin, while derivatives VIa–c were more potent than aminopyrine, mebirizole, phenylbutazone, and mefenamic acid,. Some of oxadiazole derivatives VIIa,b showed superior activity over celecoxib besides compounds VIIIa,b; which were reported to be comparable with ibuprofen as dual COX/LOX inhibition activity,.

The anti-inflammatory activity shown by the above derivatives has drawn our interest to continue our research for development of new anti-inflammatory agents. The synthesis an class="Disease">nd biological evaluation of new 2-furanone derivatives are reported herein. Also 2-furanone derivatives were used for synthesis of other heterocyclic and non-heterocyclic derivatives, which were tested as for their potential as anti-inflammatory agents against COX enzymes, LOX, and tumour necrosis factor-α (TNF-α).

Materials and methods

Synthesis of lead compounds

All commercial chemicals used as starting materials and reagents in this study were purchased from Merck (Darmstadt, Germany) an class="Disease">nd were of reagent grade. All melting points were uncorrected and measured using Electro-thermal IA 9100 apparatus (Shimadzu, Japan); IR spectra were recorded as potassium bromide pellets on a Perkin-Elmer 1650 spectrophotometer (Waltham MA, Faculty of Science, Cairo University, Cairo, Egypt. 1H-NMR spectra were determined on a Varian Mercury (300 MHz) spectrometer (Varian, Crawley, UK) and chemical shifts were expressed as ppm against TMS as internal reference (The Main Chemical warfare Laboratories, Almaza, Cairo, Egypt). Mass spectra were recorded on 70 eV (EI Ms-QP 1000 EX, Shimadzu, Japan), Faculty of Science, Cairo University, Cairo, Egypt. Microanalyses were operated using Vario, Elmentar apparatus (Shimadzu, Japan), Organic Microanalysis Unit, Faculty of Science, Cairo University, Cairo, Egypt. Column Chromatography was performed on (Merck) Silica gel 60 (particle size 0.06–0.20 mm). All the listed compounds are new except compound 1 was previously reported,.

General procedure for the synthesis of compounds 2a–c

A mixture of compound 1 (0.03 mol) an class="Disease">nd equimolar amount of aromatic aldehyde was refluxed in acetic anhydride (15 ml) with triethylamine (3–4 drops) for 4 h. After completion of reaction, the product was filtered, washed with ethanol, and recrystallised from ethanol to obtain compounds 2a–c.

5-(3,4-Dichlorophenyl)3-(2-nitrobenzylidene)-furan-2-one (2a)

Yield: 57%; m.p.: 259–261 °C; IR (KBr) ν (cm−1): 1769 (C=O), 1515,1337 (NO2); MS (EI) m/z: 363 (M + 2, 9.35%), 361 (M, 14.24%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.51–8.20 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C17H9Cl2NO4 (361.05): C, 56.51; H, 2.49; N, 3.88%. Found: C, 56.69; H, 2.81; N, 3.54%.

5-(3,4-Dichlorophenyl)3-(3-nitrobenzylidene)-furan-2-one (2b)

Yield: 90%; m.p.: 230–232 °C; IR (KBr) ν (cm−1): 1781 (C=O), 1519,1345 (NO2); MS (EI) m/z: 363 (M + 2, 23.28%), 361 (M, 34.48%), 173 (benzoyl, 100%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.23–8.67 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C17H9Cl2NO4 (361.05): C, 56.51; H, 2.49; N, 3.88%. Found: C, 56.26; H, 2.35; N, 3.76%.

5-(3,4-Dichlorophenyl)3-(4-dimethylaminobenzylidene)-furan-2-one (2c)

Yield: 73%; m.p.: 204–206 °C; IR (KBr) ν (cm−1): 1748 (C=O); MS (EI) m/z: 361 (M + 2, 12.99%), 359 (M, 19.98%); 1H-n class="Chemical">NMR (DMSO-d6, 300 MHz) δ (ppm): 3.05 (s, 6H, N(CH3)2), 6.75–8.11 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C19H15Cl2NO2 (359.05): C, 63.51; H, 4.18; N, 3.90%. Found: C, 63.29; H, 3.96; N, 3.98%.

General procedure for the synthesis of compounds 3a–c

A solution of the furanone derin class="Chemical">vatives 2a–c (0.01 mol) and ammonium acetate (7.7 g, 0.1 mol) in acetic acid (10 ml) was refluxed for 3 h. The reaction mixture was left to cool at room temperature and the product obtained was filtered off, recrystallised from ethanol to give compounds 3a–c.

5-(3,4-Dichlorophenyl)-3-(2-nitrobenzylidene)-1H-pyrrol-2-one (3a)

Yield: 80%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3140 (NH), 1698 (C=O), 1514, 1350 (n class="Chemical">NO2); MS (EI) m/z: 362 (M + 2, 10.78%), 360 (M+, 16.29%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 6.80–8.17 (m, 9H, Ar-H + CH methyne), 10.72 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C17H10Cl2N2O3 (360.02): C, 56.67; H, 2.78; N, 7.78%. Found: C, 56.81; H, 2.55; N, 7.46%.

5-(3,4-Dichlorophenyl)-3-(3-nitrobenzylidene)-1H-pyrrol-2-one (3b)

Yield: 70%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3143 (NH), 1704 (C=O), 1517, 1355 (n class="Chemical">NO2); MS (EI) m/z: 362 (M + 2, 67.3%), 360 (M+, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.05–8.57 (m, 9H, Ar-H + CH methyne), 10.68 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C17H10Cl2N2O3 (360.02): C, 56.67; H, 2.78; N, 7.78%. Found: C, 56.52; H, 2.45; N, 7.43%.

5-(3,4-Dichlorophenyl)-3-(4-dimethylaminobenzylidene)-1H-pyrrol-2-one (3c)

Yield: 56%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3697 (NH), 1673 (C=O); MS (EI) m/z: 360 (M + 2, 43.58%), 358 (M+, 62%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.98 (s, 6H, N(CH3)2), 6.46–8.37 (m, 9H, Ar-H + CH methyne), 10.37 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C19H16Cl2N2O (358.05): C, 63.52; H, 4.49; N, 7.80%. Found: C, 63.21; H, 4.56; N, 7.34%.

General procedure for the synthesis of compounds 4a–c

To a solution of the furanone 2a–c (0.01 mol) in absolute n class="Chemical">ethanol (20 ml), benzylamine (1.07 ml, 0.01 mol) was added and the reaction mixture was refluxed for 5 h. The product was filtered off, washed with ethanol, and finally recrystallised from ethanol to give the amides 4a–c.

N-benzyl-2-(2-nitrobenzylidene)-4-(3,4-dichlorophenyl)-4-oxobutanamide (4a)

Yield: 30%; m.p.: 250–252 °C; IR (KBr) ν (cm−1): 3310 (NH), 1681, 1647 (2 C=O), 1559, 1336 (n class="Chemical">NO2); MS (EI) m/z: 468 (M+, 0.33%), 91 (tropylium, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.40 (s, 2H, CH2–C=O), 4.36 (dd, 2H, CH2–NH), 7.10 (s, 1H, NH, D2O-exchangable), 7.11–8.80 (m, 13H, Ar-H + CH-methyne); Anal. Calcd. for C24H18Cl2N2O4 (468.07): C, 61.42; H, 3.87; N, 5.97%. Found: C, 61.32; H, 3.51; N, 5.82%.

N-benzyl-2-(3-nitrobenzylidene)-4-(3,4-dichlorophenyl)-4-oxobutanamide (4b)

Yield: 70%; m.p.: 124–126 °C; IR (KBr) ν (cm−1): 3312 (NH), 1676, 1648 (2 C=O), 1530, 1350 (n class="Chemical">NO2); MS (EI) m/z: 468 (M+, 0.29%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.61 (s, 2H, CH2-CO), 4.21 (dd, 2H, CH2–NH), 7.05–8.35 (m, 12H, Ar-H + CH-methyne + s, 1H, NH, D2O-exchangable); Anal. Calcd. for C24H18Cl2N2O4 (468.07): C, 61.42; H, 3.87; N, 5.97%. Found: C, 61.35; H, 3.74; N, 5.82%.

N-benzyl-2-(4-dimethylaminobenzylidene]-4-(3,4-dichlorophenyl)-4-oxobutanamide (4c)

Yield: 40%; m.p.: 241–243 °C; IR (KBr) ν (cm−1): 3300 (NH), 1756, 1670 (2 C=O); MS (EI) m/z: 468 (M + 2, 1.73%), 466 (M, 3.15%), 448 (M+-n class="Chemical">H2O, 56.15%), 91 (tropylium, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.88 (s,6H, N(CH3)2), 3.26 (s, 2H, CH2-CO), 4.20 (dd, 2H, CH2–NH), 6.93 (s, 1H, NH, D2O-exchangable), 6.69–7.43 (m, 13H, Ar-H + CH-methyne); Anal. Calcd. for C26H24Cl2N2O2 (466.09): C, 66.81; H, 5.18; N, 5.99%. Found: C, 66.75; H, 5.24; N, 5.86%.

General procedure for the synthesis of compounds 5a–c

A solution of the furanone 2a–c (0.01 mol) an class="Disease">nd phenyl hydrazine 3 ml in Na ethoxide (10 ml) was refluxed for 3 h. The product obtained was filtered, washed with water, and recrystallised from ethanol to give compounds 5a–c.

6-(3,4-Dichlorophenyl)-4-(2-nitrobenzylidene)-1-phenyl-1,4-dihydropyridazin-3(2H)-one (5a)

Yield: 72%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3317 (NH), 1629 (C=O), 1556, 1320 (n class="Chemical">NO2); MS (EI) m/z: 451 (M+, 0.49%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.46–8.77 (m, 15H, Ar-H + CH-methyne + NH-D2O exchangeable); Anal. Calcd. for C23H15Cl2N3O3 (451.04): C, 61.08; H, 3.34; N, 9.29%. Found: C, 61.29; H, 3.74; N, 9.35%.

6-(3,4-Dichlorophenyl)-4-(3-nitrobenzylidene)-1-phenyl-1,4-dihydropyridazin-3(2H)-one (5b)

Yield: 69%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3456 (NH), 1671 (C=O), 1549, 1328 (n class="Chemical">NO2); MS (EI) m/z: 451 (M+, 1.56%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.16–8.49 (m, 15H, Ar-H + CH-methyne + NH-D2O exchangeable); Anal. Calcd. for C23H15Cl2N3O3 (451.04): C, 61.08; H, 3.34; N, 9.29%. Found: C, 61.28; H, 3.61; N, 9.35%.

6-(3,4-Dichlorophenyl)-4-(4-dimethylaminobenzylidene)-1-phenyl-1,4-dihydropyridazin-3(2H)-one (5c)

Yield: 43%; m.p.: >300 °C; IR (KBr) ν (cm−1): 3300 (NH), 1655 (C=O); MS (EI) m/z: 449 (M+, 1.63%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.86 (s,6H, N(CH3)2), 6.55–8.51 (m, 15H, Ar-H + CH-methyne + NH-D2O exchangeable); Anal. Calcd. for C25H21Cl2N3O (449.04): C, 66.67; H, 4.70; N, 9.33%. Found: C, 66.46; H, 5.12; N, 9.17%.

General procedure for the synthesis of compounds 6a–c

To a solution of the furanones 2a–c (0.01 mol) in absolute n class="Chemical">ethanol (20 ml), hydrazine hydrate (3.5 ml, 0.11 mol) was added. The reaction mixture was left at room temperature with occasional shaking until complete dissolving and poured onto ice water. The product obtained 6a–c was filtered off, washed with hexane.

4-(3,4-Dichlorophenyl)-2-(2-nitrobenzylidene)-4-oxo-butanehydrazide (6a)

Yield: 65%; m.p.: 164–166 °C; IR (KBr) ν (cm−1): 3322 (NH), 3250 (NH2), 1703,1670 (2 C=O), 1521, 1343 (NO2); MS (EI) m/z: 395 (M + 2, 0.37%), 393 (M+, 0.47%), 364 (M + 2 – NHNH2, 21.29%), 362 (M – NHNH2, 31.7%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.17 (s, 2H, CH2), 4.55 (s, 2H, NH2, D2O-exchangable), 6.87 (s, 1H, NHCO, D2O-exchangable), 7.32–8.06 (m, 8H, Ar-H + CH-methyne); Anal. Calcd. for C17H13Cl2N3O4 (393.04): C, 51.91; H, 4.33; N, 10.69%. Found: C, 51.77; H, 4.51; N, 10.58%.

4-(3,4-Dichlorophenyl)-2-(3-nitrobenzylidene)-4-oxo-butanehydrazide (6b)

Yield: 58%; m.p.: 160–162 °C; IR (KBr) ν (cm−1): 3315 (NH), 3257 (NH2), 1697,1656 (2 C=O), 1528, 1360 (NO2); MS (EI) m/z: 393 (M+, 0.27%), 375 (M – H2O, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.24 (s, 2H, CH2), 4.57 (s, 2H, NH2, D2O-exchangable), 6.92 (s, 1H, NHCO, D2O-exchangable), 7.35–8.32 (m, 8H, Ar-H + CH-methyne); Anal. Calcd. for C17H13Cl2N3O4 (393.04): C, 51.91; H, 4.33; N, 10.69%. Found: C, 51.75; H, 4.55; N, 10.74%.

4-(3,4-Dichlorophenyl)-2-(4-dimethylaminobenzylidene)-4-oxo-butanehydrazide (6c)

Yield: 56%; m.p.: 154–156 °C; IR (KBr) ν (cm−1): 3310 (NH), 3258 (NH2), 1751,1672 (2 C=O); MS (EI) m/z: 393 (M + 2, 9.38%), 391 (M+, 14.69%), 364 (M + 2 – NHNH2, 32.60%), 360 (M – NHNH2, 47.87%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.82 (s, 2H, CH2), 2.92 (s, 6H, N(CH3)2), 4.39 (s, 2H, NH2, D2O-exchangable), 6.73 (s, 1H, NHCO, D2O-exchangable), 6.67–7.61 (m, 8H, Ar-H + CH-methyne); Anal. Calcd. for C19H19Cl2N3O2 (391.01): C, 58.31; H, 4.86; N, 10.74%. Found: C, 58.66; H, 5.05; N, 10.77%.

General procedure for the synthesis of compounds 7a–c

Method 1: A solution of hydrazides n class="Chemical">6a–c (0.01 mol) in HCl/AcOH (1:3) was refluxed for 3 h. The solid that separated after concentration and cooling was recrystallised from ethanol to obtain compounds 7a–c.

Method 2: To a solution of the furanones 2a–c (0.01 mol) in absolute n class="Chemical">ethanol (20 ml), hydrazine hydrate (3.5 ml, 0.11 mol) was added. The reaction mixture was refluxed for 4 h, then cooled and poured onto ice water. The product obtained 7a–c was filtered off, washed with hexane.

3-(3,4-Dichlorophenyl)-5-[(2-nitropheny)l-methyl]-1H-pyridazin-6-one (7a)

Yield: 85%; m.p.: 224–226 °C; IR (KBr) ν (cm−1): 3187 (NH), 1655 (C=O), 1517 + 1343 (NO2); MS (EI) m/z: 377 (M + 2, 2.63%), 375 (M+, 3.8%), 330 (M + 2-NO2, 63.21%), 329 (M – NO2, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 4.13 (s, 2H, CH2), 7.49–8.00 (m, 8H, Ar-H), 13.32 (s, 1H, NH-pyridazinone, D2O-exchangable); Anal. Calcd. for C17H11Cl2N3O3(375.04): C, 54.40; H, 2.93; N, 11.20%. Found: C, 54.72; H, 3.05; N, 11.08%.

3-(3,4-Dichlorophenyl)-5-[(3-nitropheny)l-methyl]-1H-pyridazin-6-one (7b)

Yield: 43%; m.p.: 257–259 °C; IR (KBr) ν (cm−1): 3203 (NH), 1653 (C=O), 1527 + 1346 (n class="Chemical">NO2); MS (EI) m/z: 377 (M + 2, 6.56%), 375 (M+, 10.06%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 4.01 (s, 2H, CH2), 7.59–8.25 (m, 8H, Ar-H), 13.34 (s, 1H, NH-pyridazinone, D2O-exchangable); Anal. Calcd. for C17H11Cl2N3O3(375.04): C, 54.40; H, 2.93; N, 11.20%. Found: C, 54.32; H, 2.83; N, 11.32%.

3-(3,4-Dichlorophenyl)-5-[(4-dimethylaminopheny)l-methyl]-1H-pyridazin-6-one (7c)

Yield: 87%; m.p.: 229–231 °C; IR (KBr) ν (cm−1): 3164 (NH), 1651 (C=O); MS (EI) m/z: 377 (M + 4, 12.06%), 375 (M + 2, 67.79%), 373 (M+, 100%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.81 (s, 6H, N(CH3)2), 3.70 (s, 2H, CH2), 6.62–8.06 (m, 8H, Ar-H), 13.19 (s, 1H, NH-pyridazinone, D2O-exchangable); Anal. Calcd. for C19H17Cl2N3O (373.09): C, 61.13; H, 4.56; N, 11.26%. Found: C, 61.33; H, 4.54; N, 10.99%.

General procedure for the synthesis of compounds 8a–c

To a solution of the hydrazides n class="Chemical">6a–c (0.01 mol) in dry benzene (20 ml), benzoyl chloride (1.4 ml, 0.01 mol) was added. The reaction mixture was heated under reflux for 2 h. The solvent was evaporated, and the solid obtained was washed thoroughly with ethanol, drained, and recrystallised from hexane to give compounds 8a–c.

2-Benzoyl-5-(2-nitrobenzylidene)-3-(3,4-dichlorophenyl)-1H-pyridazin-6-one (8a)

Yield: 84%; m.p.: 222–224 °C; IR (KBr) ν (cm−1): 3275 (NH), 1740,1660 (2 C=O),1512, 1343 (n class="Chemical">NO2); MS (EI) m/z: 481 (M + 2, 1.17%), 479 (M+, 1.69%), 105 (benzoyl, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 6.69 (s, 1H, CH-methyne),7.48–8.20 (m, 13H, Ar-H), 11.30 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C24H15Cl2N3O4 (479.04): C, 60.02; H, 3.15; N, 8.75%. Found: C, 60.34; H, 3.01; N, 8.94%.

2-Benzoyl-5-(3-nitrobenzylidene)-3-(3,4-dichlorophenyl)-1H-pyridazin-6-one (8b)

Yield: 40%; m.p.: 150–152 °C; IR (KBr) ν (cm−1): 3250 (NH), 1717,1677 (2 C=O),1523, 1350 (n class="Chemical">NO2); MS (EI) m/z: 479 (M+, 2.82%), 105 (benzoyl, 100%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 7.03–8.59 (m, 13H, Ar-H + CH-methyne), 11.34 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C24H15Cl2N3O4 (479.04): C, 60.02; H, 3.15; N, 8.75%. Found: C, 60.12; H, 3.56; N, 8.91%.

2-Benzoyl-5-(4-dimethylaminobenzylidene)-3-(3,4-dichlorophenyl)-1H-pyridazin-6-one (8c)

Yield: 37%; m.p.: 229–231 °C; IR (KBr) ν (cm−1): 3225 (NH), 1687,1664 (2 C=O); MS (EI) m/z: 479 (M + 2, 33.09%), 474 (M+, 49.44%), 105 (benzoyl, 100%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.03 (s, 6H, N(CH3)2), 6.76–8.01 (m, 14H, Ar-H + CH-methyne), 11.17 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C26H21Cl2N3O2 (477.09): C, 65.28; H, 4.42; N, 8.78%. Found: C, 65.31; H, 4.68; N, 8.23%.

General procedure for the synthesis of compounds 9a–c

A solution of hydrazides n class="Chemical">6a–c (0.01 mol) and carbon disulphide (3 ml) in pyridine (10 ml) was refluxed for 3 h. The reaction mixture was left to cool at room temperature and poured onto ice water; the product obtained was filtered, washed with water and recrystallised from ethanol to give compounds 9a–c.

1-(3,4-Dichlorophenyl)-4-(2-nitrophenyl)-3-(2-thioxo-4,5-dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9a)

Yield: 40%; m.p.: 214–216 °C; IR (KBr) ν (cm−1): 3196 (NH), 1653 (C=O),1504, 1340 (n class="Chemical">NO2), 1254 (C=S); MS (EI) m/z: 435 (M+, 0.31%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 4.13 (s, 2H, CH2), 7.36–8.00 (m, 8H, Ar-H + CH-methyne), 13.32 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C18H11Cl2N3O4S (435.04): C, 49.56; H, 2.54; N, 9.63%. Found: C, 49.38; H, 2.76; N, 9.54%.

1-(3,4-Dichlorophenyl)-4-(3-nitrophenyl)-3-(2-thioxo-4,5-dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9b)

Yield: 58%; m.p.: 242–244 °C; IR (KBr) ν (cm−1): 3195 (NH), 1653 (C=O),1514, 1346 (n class="Chemical">NO2), 1238 (C=S); MS (EI) m/z: 435 (M+, 0.07%); 1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 3.99 (s, 2H, CH2), 7.38–8.57 (m, 8H, Ar-H + CH-methyne), 13.32 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C18H11Cl2N3O4S (435.04): C, 49.56; H, 2.54; N, 9.63%. Found: C, 49.37; H, 2.34; N, 9.41%.

1-(3,4-Dichlorophenyl)-4-(4-dimethylaminophenyl)-3-(2-thioxo-4,5-dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9c)

Yield: 89%; m.p.: 162–164 °C; IR (KBr) ν (cm−1): 3200 (NH), 1655 (C=O), 1230 (C=S); MS (EI) m/z: 433 (M+, 1.4%); n class="Chemical">1H-NMR (DMSO-d6, 300 MHz) δ (ppm): 2.84 (s, 6H, N(CH3)2), 3.72 (s, 2H, CH2), 6.65–8.59 (m, 8H, Ar-H + CH-methyne), 13.22 (s, 1H, NH, D2O-exchangable); Anal. Calcd. for C20H17Cl2N3O2S (433.04): C, 55.31; H, 3.95; N, 9.67%. Found: C, 55.64; H, 3.47; N, 9.21%.

Biological evaluation of anti-inflammatory activity

Cyclooxygenase (COX-1 and COX-2) inhibition assay

Tested compounds were dissolved in n class="Chemical">DMSO. Each compound was tested in triplicates using a COX inhibitory screening assay kit according to the manufacturer (Cayman test kit-560131, Cayman Chemical, Ann Arbor, MI). The COX inhibitor screening assay depends on direct measurement of the amount of PG2α produced in the COX reaction. Celecoxib, rofecoxib, and indomethacin were used as the positive control for inhibition of COX-1 and COX-2. An aliquot of 20 µl of each test compound or solvent (100% initial activity) was added to 950 µl of Reaction Buffer (0.1 M Tris–HCl, pH 8.0, containing 5 mM EDTA and 2 mM phenol), 10 µl of haem, and 10 µl of COX-1 or COX-2, then incubated with the enzymes at 37 °C for 10 min. The reaction was initiated by addition of 10 µl AA to all the test tubes and incubation at 37 °C for an additional 2 min. Enzyme catalysis was terminated by addition of 50 µl 1 M HCl and 100 µl of the saturated stannous chloride solution. The PGs are quantified by enzyme immunoassay (EIA) at 410 nm.

Lipoxygenase (15-LOX) inhibition assay

The experiment was performed in triplicates using Cayman’s LOX inhibitor screening assay kit (Cayman test kit-760700, Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s protocol. n class="Chemical">DMSO was used as 100% initial activity and Quercetin was used as the positive control. Briefly, in a 96-well plate, 10 µl of each test compound (dissolved in DMSO) or vehicle were pre-incubated with 90 µl of 15-LOX enzyme. The reaction was started by addition of 10 µl of substrate (AA) and the plate was shaken for at least 5 min. Then, 100 µl of chromogen supplied with the kit was added to each well to stop the enzymatic reaction and develop the colour. The absorbance was measured at 490 nm using microplate reader.

TNF-α [biotinylated] inhibition assay

The assay was performed in triplicates using TNFR2: TNF-α [biotinylated] Inhibitor Screening Assay Kit (BPS bioscience, San Diego, CA, Catalog #79756), following the manufacturer’s protocol. First, TNFR2 is coated on a 96-well plate. Next, biotinylated TNF-α is incubated with TNFR2 on the plate. Finally, the plate was treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.

Results and discussion

Chemistry

Overall, 22 new compounds an class="Disease">nd two reported compounds were synthesised as revealed in Schemes A and B. 2-Furanone derivatives 2a–c were synthesised from 4-oxobutanoic derivative 1 by reacting with aromatic aldehydes in acetic anhydride following modified Perkin reaction conditions,,.

The required 4-oxobutanoic derin class="Chemical">vative 1 was prepared by condensing dry dichlorobenzene with succinic anhydride in presence of anhydrous aluminium chloride, following Friedel–Crafts acylation reaction conditions.

As revealed in Scheme A, 2-furanone derin class="Chemical">vatives 2a–c proved to be useful precursors in the synthesis of several heterocyclic and non-heterocyclic derivatives. When they were allowed to react, separately, with ammonium acetate; pyrrol-2-one derivatives 3a–c were produced. 4-oxobutanamides 4a–c were prepared by refluxing 2-furanones 2a–c with benzylamine and 1-phenylpyridazinone 5a–c were also prepared from 2-furanones by refluxing with phenyl hydrazine according to the reported procedure,.

Scheme A.

Synthesis of compounds 2a–c to 5a–c.

Pyridazinone derin class="Chemical">vatives 7a–c can be prepared by first stirring of 2-furanone derivatives 2a–c with hydrazine hydrate to obtain hydrazide derivatives 6a–c which can be cyclised by refluxing in HCl to obtain the desired pyridazinone derivatives 7a–c. They can be prepared directly by refluxing 2-furanone derivatives 2a–c with hydrazine hydrate.

Hydrazide derin class="Chemical">vatives 6a–c were refluxed with benzoyl chloride to obtain 2-benzoylpyridazinone derivatives 8a–c.

Finally, oxadiazole-thione derin class="Chemical">vatives 9a–c were prepared via refluxing hydrazide derivatives 6a–c with carbon disulphide in pyridine,,,, as revealed in Scheme B.

Scheme B.

Synthesis of compounds 6a–c to 9a–c.

Anti-inflammatory activity results

Inflammation is a protective defence response of the body. However, during n class="Disease">inflammation, several pathological changes occur, which involve the release of common mediators of inflammation like PGs, histamine, nitric oxide, leukotrienes (LTB4), platelet-activation factor, lipoxins, and cytokines. The inflammatory response must be terminated; using anti-inflammatory compounds, when no more needed to prevent avoidable harmful biological processes. Inhibition of eicosanoids generation, in addition to the release of the pro-inflammatory cytokine; TNF-α from macrophages are used for in vitro inflammation tests.

Thus, the newly synthesised compounds were tested for their anti-inflammatory activity against isozymes n class="Gene">COX-1 and COX-2, which were determined by the COX-catalysed transformation of AA into PGH2 that was reduced to PGF2α and detected by the EIA, as shown in Table 1.

Table 1.

COX-1, COX-2, and 15-LOX enzymes inhibition activities of the synthesised compounds.

Compound number	COX1	COX 2	Selectivity indexes	LOX
	IC50 (µm)	IC50 (µm)	(SI)	IC50 (µm)
2a	4.53 ± 0.12	0.35 ± 0.01	12.94	5.10 ± 0.10
2b	6.97 ± 0.12	0.28 ± 0.01	24.89	4.40 ± 0.10
2c	3.93 ± 0.06	0.42 ± 0.02	9.36	6.13 ± 0.12
3a	8.37 ± 0.12	0.19 ± 0.01	44.05	2.33 ± 0.12
3b	6.87 ± 0.12	0.39 ± 0.01	17.62	1.87 ± 0.15
3c	5.93 ± 0.15	0.34 ± 0.01	17.44	2.21 ± 0.98
4a	11.07 ± 0.15	0.05 ± 0.00	221.40	5.47 ± 0.12
4b	13.33 ± 0.15	0.06 ± 0.00	222.17	5.87 ± 0.06
4c	11.90 ± 0.10	0.05 ± 0.00	238.00	4.67 ± 0.06
5a	12.73 ± 0.12	0.06 ± 0.00	212.17	2.70 ± 0.95
5b	13.00 ± 0.10	0.04 ± 0.00	325.00	2.43 ± 0.12
5c	11.73 ± 0.12	0.09 ± 0.00	130.33	2.97 ± 0.12
6a	9.67 ± 0.06	0.09 ± 0.00	107.44	2.83 ± 0.06
6b	10.07 ± 0.15	0.08 ± 0.00	125.88	2.47 ± 0.06
6c	8.83 ± 0.06	0.10 ± 0.01	88.30	3.17 ± 0.06
7a	7.03 ± 0.15	0.17 ± 0.01	41.35	5.47 ± 0.12
7b	6.67 ± 0.12	0.25 ± 0.01	26.68	5.87 ± 0.06
7c	8.33 ± 0.06	0.12 ± 0.01	69.42	4.67 ± 0.06
8a	10.77 ± 0.15	0.07 ± 0.00	153.86	2.33 ± 0.51
8b	12.67 ± 0.12	0.04 ± 0.00	316.75	2.47 ± 0.06
8c	13.07 ± 0.12	0.04 ± 0.00	326.75	3.17 ± 0.06
9a	9.43 ± 0.12	0.28 ± 0.01	33.68	2.07 ± 0.15
9b	10.43 ± 0.12	0.08 ± 0.00	130.38	1.63 ± 0.15
9c	8.93 ± 0.06	0.22 ± 0.01	40.59	2.00 ± 0.17
Celecoxib	14.70 ± 0.06	0.05 ± 0.00	326.67	ND
Rofecoxib	14.50 ± 0.10	0.03 ± 0.00	580.00	ND
Indomethacin	0.10 ± 0.00	0.08 ± 0.00	1.25	ND
Quercetin	ND	ND	ND	3.34 ± 0.05

Data are presented as mean ± SD of three experiments.

ND: not determined; SI = IC50 COX-1/COX-2 ratios.

COX-1, n class="Gene">COX-2, and 15-LOX enzymes inhibition activities of the synthesised compounds.

ND: not determined; SI = IC50 n class="Gene">COX-1/COX-2 ratios.

Compound 2c was the most potent n class="Gene">COX-1 inhibitor (IC50 3.93 ± 0.06 µM) among test compounds, being 39 times less active than the reference drug indomethacin (IC50=0.10 µM) indicating the selective COX-2 inhibition activity of all test compounds. Pyridazinone derivatives 5b, 8b, and 8c were the most potent selective COX-2 inhibitors (IC50=0.04 µM for the three compounds), being superior to the reference drug (celecoxib IC50=0.05 µM). While amide derivatives; 4a–c, hydrazides; 6a, 6b, N-phenyl and N-benzoylpyridazinones; 5a, 5c, 8a and oxadiazole; 9b (IC50=0.05–0.09 µM range), showed comparable activity to celecoxib as selective COX-2 inhibitors. These results indicate the high activity of hydrazides, pyridazinones, and oxadiazole; which is in consistent with previously reported activities of similar scaffolds as selective COX-2 inhibitors,,.

Studies showed that soybean n class="Gene">LOX enzyme has a wide substrate specificity, and that the oxygenation sites for the soybean LOX has been demonstrated to be at C-13 of α-linolenic acid and C-15 of AA. Therefore, the soybean LOX is most like the mammalian 15-LOX.

Consequently, the in vitro inhibitory effect of all synthesised compounds against n class="Gene">15-LOX was determined using a lipoxygenation reaction to transform AA into hydroperoxides, which were detected by the addition of a chromogen, whose results are displayed in Table 1.

Results also revealed that all the synthesised derin class="Chemical">vatives of pyrrolones 3a–c, hydrazides 6a–c, N-phenyl and N-benzoylpyridazinones; 5a–c, 8a–c, and oxadiazoles 9a–c inhibited 15-LOX (IC50 =1.63 − 3.17 µM range), 9b being the most potent 15-LOX inhibitor (IC50=1.63 ± 0.15 µM), compared to the positive control Quercetin (IC50=3.34 µM). However, furanones 2a–c, amides 4a–c, and pyridazinones 7a–c exhibited lower 15-LOX inhibitory effect.

By evaluating the COX an class="Disease">nd 15-LOX inhibition results, three compounds namely 6–(3,4-dichlorophenyl)-4–(3-nitrobenzylidene)-1-phenyl-1,4-dihydropyridazin-3(2H)-one (5b), 2-benzoyl-5–(3-nitrobenzylidene)-3–(3,4-dichlorophenyl)-1H-pyridazin-6-one (8b), and 2-benzoyl-5–(4-dimethylaminobenzylidene)-3–(3,4-dichlorophenyl)-1H-pyridazin-6-one (8c) seemed to be the best candidates as a COX-2/15-LOX dual inhibitors, which is a current subject of interest in the development of anti-inflammatory agents. This declares the expected activity of N-phenyl and N-benzoylpyridazinones derivatives as reported for some other derivatives with the same scaffold . On the other hand, compounds 5a, 5c, 6a, 6b, 8a, and 9b exhibited a little lower COX-2 inhibition but still show high dual COX-2/15-LOX inhibition activity.

Moreover, the ability to inhibit TNF-α, which is a potent pro-inflammatory chemokine was tested; resun class="Chemical">lts are shown in Table 2. The 15-LOX pathway was reported to induce inflammation through increased expression of IL-6, IFN-γ, IL-12, and TNF-α.

Table 2.

Inhibitory effects of tested compounds against TNF-α.

Compound number	TNF-α
	IC50 (nM)
2a	7.47 ± 0.12
2b	7.77 ± 1.68
2c	8.20 ± 0.10
3a	5.93 ± 0.15
3b	8.27 ± 0.12
3c	6.77 ± 0.12
4a	4.77 ± 0.12
4b	3.53 ± 0.12
4c	5.47 ± 0.12
5a	4.93 ± 0.06
5b	3.27 ± 0.12
5c	3.57 ± 0.12
6a	5.87 ± 0.12
6b	4.10 ± 0.10
6c	6.17 ± 0.06
7a	8.53 ± 0.12
7b	8.17 ± 0.06
7c	7.57 ± 0.06
8a	3.83 ± 1.44
8b	3.47 ± 0.06
8c	2.90 ± 0.10
9a	5.57 ± 0.06
9b	4.33 ± 0.12
9c	6.27 ± 0.15
Certolizumab	6.70 ± 0.12

Data are presented as mean ± SD of three experiments.

Inhibitory effects of tested compounds against Tn class="Chemical">NF-α.

Sixteen compounds of our newly synthesised tested compoun class="Disease">nds; pyrrolone 3a, amides 4a–c, N-phenylpyridazinones 5a–c, hydrazides 6a–c, N-benzoylpyridazinones 8a–c, and oxadiazoles 9a–c showed higher activities (IC50 = 2.90 − 6.27 µM range) than the used reference inhibitor Certolizumab (IC50=6.70 µm). While compound 3c showed comparable activity with IC50=6.77 µM. Compound 8c showed the lowest IC50 value for TNF-α inhibition, indicating that this activity may be a consequence of 15-LOX inhibition.

To analyse the structure–activity relationship (SAR) of the tested compoun class="Disease">nds from the previous results, it is obvious that our three newly synthesised furanones are totally inactive towards all the tested enzymes. But upon their conversion to other heterocyclic and non-heterocyclic compounds the biological activities appear as revealed in Figure 2 and explained as follows:

Figure 2.

Structure–activity relationship of the tested compounds against the tested enzymes.

3 Pyrrolone derin class="Chemical">vatives 3a–c acquired high activity as LOX-inhibitors, only one of them having 3-nitrobenzylidene substituent (3b) showed high activity as TNF-α inhibitor. They still have no significant activities as COX-2 inhibitors.

Upon ring opening and formation of n class="Chemical">amide derivatives 4a–c, a high TNF-α inhibition appears with significant selective COX-2 inhibition, but no significant LOX-inhibition observed.

Also, ring opening and n class="Chemical">hydrazides formation in 6a–c showed activity against 15-LOX and TNF-α, while 6a,b having 2-nitrobenzylidene and 3-nitrobenzylidene substituents showed high activity as selective COX-2 inhibitors.

Conversion of furanones to n class="Chemical">pyridazinines 7a–c did not affect their biological activities as they were still inactive. But formation of N-phenylpyridazinones 5a–c and N-benzoylpyridazinones 8a–c was a perfect pathway for highly potent derivatives against all the tested enzymes with desirable dual COX-2/15-LOX inhibition activities for compounds 5b, 8b, and 8c indicating the important influence of presence of 3-nitrobenzylidene substituent in both pyridazinones (5b, 8b) and 4-dimethylaminobenzylidene in N-benzoylpyridazinone (8c).

Finally, three oxadiazole derin class="Chemical">vatives 9a–c showed high activity against 15-LOX and TNF-α, while two derivatives, having 2-nitrobenzylidene and 4-dimethylaminobenzylidene substituents, 9a and 9c, respectively, showed high activity as selective COX-2 inhibitors.

Synthesis of compounds 2a–c to n class="Chemical">5a–c.

Synthesis of compounds n class="Chemical">6a–c to 9a–c.

Conclusion

In conclusion, as presented in this study, novel 2-furanone derin class="Chemical">vatives were synthesised and used to prepare novel hydrazides, 2-pyrrolone, 2-pyridazinone, and oxadiazole derivatives. All the synthesised compounds were investigated for their anti-inflammatory activity; the biological results revealed that N-phenylpyridazinone 5b, N-benzoylpyridazinones 8b and 8c showed promising activity as dual COX-2/15-LOX inhibitors along with high TNF-α inhibition activity. Thus, these compounds might be promising anti-inflammatory candidates and may need further studies to be used clinically.

Click here for additional data file.